CYTKCytokinetics, Incorporated
$62.93+29% 1Y
$62.93
$47.8352 weeks$84.88
The financials
Cytokinetics, Incorporated by the numbers
Cytokinetics, Incorporated (CYTK) reported revenue of $29M in Q2 2026 (quarter ended Jun 30, 2026), down 57% from the same quarter a year earlier. That came with net loss of $199M. For the full year FY2025, revenue was $88M (+377% year on year) and net income −$785M. Its largest product in Q2 2026 was Net Product at $25M, 89% of the disclosed total, well ahead of Collaboration at 11%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $29M | $67M | −57% |
| Operating income | −$179M | −$112M | n/a |
| Net income | −$199M | −$134M | n/a |
| Diluted EPS | −$1.50 | −$1.12 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Net Product | $25M | 89% |
| Collaboration | $3.3M | 11% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $28.6M (+48%)
Collaboration grew +36% year on yearLicense And Milestone -100% year on year
Segment Latestquarter on quarteryear on year
- Net Product$25.3M$25.3Mquarter on quarter +429%year on year n/a+429%n/a
- Collaboration$3.3M$3.3Mquarter on quarter +25%year on year +36%+25%+36%
- License And Milestone$0.00$0.00quarter on quarter -100%year on year -100%-100%-100%
On our screens:Most shorted stocks